Search

Displaying results 2641 - 2650 of 10000 in total
  1. Target

    Transient receptor potential cation channel subfamily V member 2

    go.drugbank.com/bio_entities/BE0009158
    TargetHumans

    Calcium-permeable, non-selective cation channel (PubMed:10201375). Seems to be regulated, at least in part, by growth factors, such as IGF1, PDGF and morphogenetic neuropeptide/head activator. May transduce physical stimuli in mast cells...

    Polypeptides: Transient receptor potential cation channel subfamily V member 2Synonyms: Vanilloid receptor-like protein 1
  2. Target

    Ankyrin repeat and protein kinase domain-containing protein 1

    go.drugbank.com/bio_entities/BE0009411
    TargetHumans

    Polypeptides: Ankyrin repeat and protein kinase domain-containing protein 1
  3. Target

    Transient receptor potential cation channel subfamily M member 3

    go.drugbank.com/bio_entities/BE0009808
    TransporterHumans

    Suggested to function as an ionotropic steroid receptor in beta-cell, indeed pregnenolone sulfate leads to Ca(2+) influx and enhanced insulin secretion.

    Polypeptides: Transient receptor potential cation channel subfamily M member 3Synonyms: Long transient receptor potential channel 3
  4. Drug

    Raltitrexed

    go.drugbank.com/drugs/DB00293
    ApprovedInvestigational

    Raltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.

  5. Drug

    Aceclidine

    go.drugbank.com/drugs/DB13262
    Approved

    [A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768] … Aceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma.

    Categories: Cholinergic Receptor Agonist
  6. Drug

    Nerofe

    go.drugbank.com/drugs/DB14786
    Investigational

    Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).

  7. Drug

    Rilonacept

    go.drugbank.com/drugs/DB06372
    ApprovedInvestigational

    Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) … Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1.

    Synonyms: IL-1 TRAP, IL-1-TRAPCategories: Receptors, Interleukin-1 Type I, Interleukin-1 Receptor Accessory Protein
  8. Drug

    GR270773

    go.drugbank.com/drugs/DB06427
    Investigational

    NCT00089986 (completed with results, treatment of suspected or confirmed gram-negative severe sepsis in adults, comparing GR270773 with a placebo). … GR270773, was investigated in two clinical trials for its potential to treat sepsis: NCT00158769 (completed, comparing the effects of infusion between healthy adults and those with damaged livers) and

  9. Drug

    Nonivamide

    go.drugbank.com/drugs/DB11324
    Approved

    Nonivamide is found in herbs and spices. It is an alkaloid from the Capsicum species. … Nonivamide is a flavoring ingredient. Nonivamide is an organic compound and a capsaicinoid. It is an amide of pelargonic acid and _vanillylamine_.

  10. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system. … Simoctocog alfa is a glycoprotein consisting of 1440 amino acids with an approximate molecular mass of 170 kDa, comprising the FVIII domains A1-A2 + A3-C1-C2 whereas the B-domain, present in the full-length